The novel mRNA-based vaccines against SARS-CoV-2 display encouraging safety and efficacy profiles. However, there is a paucity of data regarding their immunogenicity and safety in patients with liver diseases (PWLD), especially in those with cirrhosis. We prospectively assessed anti-SARS-CoV-2 S-spike IgG antibodies and neutralizing activity in fully vaccinated PWLD ( n = 87) and controls ( n = 40). Seroconversion rates were 97.4% (37/38) in cirrhotic PWLD, 87.8% (43/49) in non-cirrhotic PWLD and 100% (40/40) in controls. Adequate neutralizing activity was detected in 92.1% (35/38), 87.8% (43/49) and 100% (40/40) of cirrhotics, non-cirrhotics and controls, respectively. On multivariable analysis, immunosuppressive treatment was negatively correlated with anti-SARS-CoV-2 antibody titers (coefficient (SE): −2.716 (0.634), p < 0.001) and neutralizing activity (coefficient (SE): −24.379 (4.582), p < 0.001), while age was negatively correlated only with neutralizing activity (coefficient (SE): −0.31(0.14), p = 0.028). A total of 52 responder PWLD were reassessed approximately 3 months post-vaccination and no differences were detected in humoral responses between cirrhotic and non-cirrhotic PWLD. No significant side effects were noted post vaccination, while no symptomatic breakthrough infections were reported during a 6-month follow up. Overall, our study shows that m-RNA-based SARS-CoV-2 vaccines are safe and efficacious in PWLD. However, PWLD under immunosuppressive treatment and those of advanced age should probably be more closely monitored after vaccination.
【저자키워드】 SARS-CoV-2, vaccination, Immunosuppression, liver diseases, cirrhosis, 【초록키워드】 Efficacy, liver diseases, anti-SARS-CoV-2, SARS-CoV-2 vaccine, Neutralizing activity, IgG antibody, Humoral response, anti-SARS-CoV-2 antibody, IgG antibodies, symptomatic, cirrhosis, Patient, Control, age, Breakthrough infection, humoral responses, Antibody titers, Liver disease, Immunosuppressive treatment, Safe, paucity of data, Side effect, no difference, no differences, advanced age, multivariable analysis, profiles, coefficient, seroconversion rates, post vaccination, mRNA-based vaccine, controls, reported, correlated, Adequate, 【제목키워드】 response,